Faecalibacterium

Faecalibacterium genus relative abundance was significantly higher in anti-PD-1 responders versus non-responders in a newly recruited independent cohort of 132 metastatic melanoma patients (n=87 responders, n=45 non-responders; p=0.018 by Wilcoxon rank sum test), supporting its role as a gut microbiota marker of immunotherapy response.

PMID: 34941392

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma

In melanoma patients treated with ICB (n=123), Faecalibacterium genus abundance was numerically higher in patients reporting sufficient dietary fiber intake (≥20 g/day) and no probiotic use — the subgroup with significantly longer progression-free survival (median PFS not reached versus 13 months, P=0.015 vs. all other groups) — though the Faecalibacterium difference per se did not reach statistical significance due to small group size (n=22 in optimal group).

PMID: 34941392

D004043 Dietary Fiber D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma

Faecalibacterium genus was significantly enriched in anti-PD-1 responders versus non-responders in the gut microbiome of 43 metastatic melanoma patients (30R, 13NR; FDR-adjusted pairwise comparisons and LEfSe; p<0.01), establishing the original human evidence for genus-level enrichment as a marker of immunotherapy response.

PMID: 29097493

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma

High Faecalibacterium abundance (above median) was associated with significantly prolonged progression-free survival compared to low abundance in 39 anti-PD-1-treated metastatic melanoma patients (p=0.03; multivariate Cox HR=2.95, 95% CI 1.31–7.29), identifying it as an independent gut microbiome predictor of immunotherapy outcome.

PMID: 29097493

D000082082 Immune Checkpoint Inhibitors D008545 Melanoma D000077982 Progression-Free Survival H00038 Melanoma

Faecalibacterium genus abundance was significantly positively correlated with CD8+ T cell density in pre-treatment tumors of melanoma patients on anti-PD-1 therapy (r²=0.42, p<0.01; n=15 matched tumor-microbiome samples), linking gut microbiome composition to intratumoral anti-tumor immunity.

PMID: 29097493

D000069196 Gastrointestinal Microbiome D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma